5 Biotech Stocks To Buy Right Now

Image: Bigstock

Many of the companies in the biotech sector have had a rough past few weeks with many stocks hitting their lowest levels since January. That being said, here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.

Vertex Pharmaceuticals Inc. (VRTX - Free Report)

Zacks Rank #2 (Buy)

Vertex Pharmaceuticals is a Boston based biotech firm that specializes in the development and production of Cystic Fibrosis treatments. Vertex was recently upgraded to a Zacks Rank #2 (Buy) on the back of earnings estimate revisions for the current fiscal year trending in the right direction. On top of 3.4% projected growth this year, the Zacks Consensus Estimate calls for VRTX’s fiscal 2020 earnings to climb 37% above our 2019 estimate. This bottom-line growth is projected to be fueled by estimated revenue growth of 16.7% this year and a further 22% expansion in 2020. Vertex currently earns a Style Score of "B" for Growth.

Gilead Sciences Inc. (GILD - Free Report)

Zacks Rank #2 (Buy)

California-based Gilead Sciences is a drug company primarily focused on developing antiviral drugs. Gilead had 11 upwards earnings estimate revisions over the past 60 days, compared to just 1 downward revision for fiscal 2019. This shows analysts are more optimistic about the company’s current year earnings. Gilead also boasts a Zacks Style Score of "A" for Value due to multiple factors including its low P/E of 9.23 compared to its industry’s average of 23.89. The combination of good value and expected earnings growth could make Gilead a great addition to a portfolio.

Repligen Corp. (RGEN - Free Report)

Zacks Rank #1 (Strong Buy)

Repligen is a biotech company based out of Massachusetts that develops and produces materials used to manufacture biological drugs. Repligen is the first of two Zacks Rank #1 (Strong Buy) companies on this list. The Zacks Consensus Estimates for Repligen’s earnings growth are 28.8% and 19% for fiscal year 2019 and 2020, respectively. These earnings growth rates are accompanied by expected revenue growth of 30% and 16.9% for fiscal year 2019 and 2020, respectively. This expected growth helped earn Repligen a Zacks Style Score of "A" for Growth.

1 2
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any specific ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.